Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Kita Y, Goto T, Akamatsu S, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: opportunities and challenges. Cancers (Basel). 2018;10(10):345. doi:10.3390/cancers10100345.
   Web of Science ®Google Scholar
• Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–499. doi:10.1146/annurev-med-051517-011947.
   PubMed Web of Science ®Google Scholar
• Philippou Y, Sjoberg H, Lamb AD, Camilleri P, Bryant RJ. Harnessing the potential of multimodal radiotherapy in prostate cancer. Nat Rev Urol. 2020;17(6):321–338. doi:10.1038/s41585-020-0310-3.
   PubMed Web of Science ®Google Scholar
• Ma TM, Lilleby O, Lilleby WA, Kishan AU. Ablative radiotherapy in prostate cancer: stereotactic body radiotherapy and high dose rate brachytherapy. Cancers (Basel). 2020;12(12):3606. doi:10.3390/cancers12123606.
   Web of Science ®Google Scholar
• Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell. 2018;174(2):433–447.e19. doi:10.1016/j.cell.2018.05.036.
   PubMed Web of Science ®Google Scholar
• van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10(1):5251. doi:10.1038/s41467-019-13084-7.
   PubMed Web of Science ®Google Scholar
• Rodrigues DN, Boysen G, Sumanasuriya S, Seed G, Marzo AM, de Bono J. The molecular underpinnings of prostate cancer: impacts on management and pathology practice. J Pathol. 2017;241(2):173–182. doi:10.1002/path.4826.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297–303. doi:10.1038/nature23306.
   PubMed Web of Science ®Google Scholar
• Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, et al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med. 2018;10(1):85. doi:10.1186/s13073-018-0595-5.
   PubMed Web of Science ®Google Scholar
• Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428–11436. doi:10.1073/pnas.1902651116.
   PubMed Web of Science ®Google Scholar
• Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol. 2013;228(8):1676–1687. doi:10.1002/jcp.24329.
   PubMed Web of Science ®Google Scholar
• Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785–797. doi:10.1038/nrc2696.
   PubMed Web of Science ®Google Scholar
• Manning AL, Dyson NJ. pRB, a tumor suppressor with a stabilizing presence. Trends Cell Biol. 2011;21(8):433–441. doi:10.1016/j.tcb.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Marshall AE, Roes MV, Passos DT, DeWeerd MC, Chaikovsky AC, Sage J, et al. RB1 deletion in retinoblastoma protein pathway-disrupted cells results in DNA damage and cancer progression. Mol Cell Biol. 2019;39(16):e00105-19. doi:10.1128/MCB.00105-19.
   PubMed Web of Science ®Google Scholar
• Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329–334. doi:10.1038/nature10733.
   PubMed Web of Science ®Google Scholar
• Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al., PCF/SU2C International Prostate Cancer Dream Team. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173(7):1770–1782.e14. doi:10.1016/j.cell.2018.04.034.
   PubMed Web of Science ®Google Scholar
• Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, et al. SPOP mutation leads to genomic instability in prostate cancer. Elife. 2015;4:e09207. doi:10.7554/eLife.09207.
   PubMed Web of Science ®Google Scholar
• Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, et al. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur Urol. 2020;77(3):333–341. doi:10.1016/j.eururo.2019.09.036.
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi:10.1038/nrc4016.
   PubMed Web of Science ®Google Scholar
• Tricoli JV, Gumerlock PH, Yao JL, Chi SG, D'Souza SA, Nestok BR, deVere White RW. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosom Cancer. 1996;15(2):108–114. doi:10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140(3):384–396. doi:10.1016/j.cell.2009.12.032.
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909–923. doi:10.1038/nrc2012.
   PubMed Web of Science ®Google Scholar
• Gannon HS, Woda BA, Jones SN. ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice. Cancer Cell. 2012;21(5):668–679. doi:10.1016/j.ccr.2012.04.011.
   PubMed Web of Science ®Google Scholar
• Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V, Fåhraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012;21(1):25–35. doi:10.1016/j.ccr.2011.11.016.
   PubMed Web of Science ®Google Scholar
• Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A. 1999;96(26):14973–14977. doi:10.1073/pnas.96.26.14973.
   PubMed Web of Science ®Google Scholar
• Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001;15(9):1067–1077. doi:10.1101/gad.886901.
   PubMed Web of Science ®Google Scholar
• Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10. doi:10.1186/s12943-016-0577-4.
   PubMed Web of Science ®Google Scholar
• Chaiswing L, Weiss HL, Jayswal RD, Clair DKS, Kyprianou N. Profiles of radioresistance mechanisms in prostate cancer. Crit Rev Oncog. 2018;23(1-2):39–67. doi:10.1615/CritRevOncog.2018025946.
   PubMedGoogle Scholar
• Tsao T, Beretov J, Ni J, Bai X, Bucci J, Graham P, Li Y. Cancer stem cells in prostate cancer radioresistance. Cancer Lett. 2019;465:94–104. doi:10.1016/j.canlet.2019.08.020.
   PubMed Web of Science ®Google Scholar
• Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015;5:90 doi:10.3389/fonc.2015.00090.
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83. doi:10.1126/science.aah4199.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Sexton CR, Mayhew CN. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med. 2006;6(7):749–757. doi:10.2174/1566524010606070749.
   PubMed Web of Science ®Google Scholar
• van Harn T, Foijer F, van Vugt M, Banerjee R, Yang F, Oostra A, et al. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev. 2010;24(13):1377–1388. doi:10.1101/gad.580710.
   PubMed Web of Science ®Google Scholar
• Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 2010;24(13):1364–1376. doi:10.1101/gad.1917310.
   PubMed Web of Science ®Google Scholar
• Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene. 2006;25(5):746–755. doi:10.1038/sj.onc.1209103.
   PubMed Web of Science ®Google Scholar
• Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 2004;32(1):25–34. doi:10.1093/nar/gkg919.
   PubMed Web of Science ®Google Scholar
• Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 2018;24(7):947–953. doi:10.1038/s41591-018-0043-5.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170(6):1062–1078. doi:10.1016/j.cell.2017.08.028.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–737. doi:10.1038/nrc.2017.87.
   PubMed Web of Science ®Google Scholar
• Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020;31(8):107669. doi:10.1016/j.celrep.2020.107669.
   PubMed Web of Science ®Google Scholar
• Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi:10.1038/s41572-020-00243-0.
   PubMed Web of Science ®Google Scholar